How can I use market access consultancies to support payer strategy during a rare disease launch?

Market access consultancies can be very useful in a rare disease launch because they bring structured insight, payer relationships, and launch experience that may be hard to build quickly in-house. The key is to use them for decision support and execution acceleration, not as a substitute for your own payer strategy.

Where they can help most

1. Shape the payer value story

Rare disease products often need a very specific story around:

• unmet need
• diagnostic delay
• disease burden
• clinical meaningfulness of outcomes
• caregiver and societal impact
• small patient populations and uncertainty

A consultancy can help refine:

• the value proposition
• core payer messages
• evidence framing for different stakeholders
• comparison against current standard of care or no treatment

2. Build payer evidence strategy

For rare disease launches, evidence is often limited at approval. Consultants can help design:

• evidence gaps assessment
• HEOR plans
• real-world evidence strategy
• burden-of-illness research
• budget impact models
• subgroup/value segment analyses

They can also help decide which endpoints and data are most compelling for payers.

3. Test payer assumptions before launch

Consultancies can run:

• payer advisory boards
• message testing
• market research
• objection mapping
• scenario testing for coverage, tiering, and restrictions

This helps identify where payers may challenge:

• clinical relevance
• durability of effect
• long-term safety
• eligible population size
• cost offsets
• diagnostic certainty

4. Support segmentation and access planning

Rare diseases often require a nuanced approach by payer type. A consultancy can help segment:

• national vs regional payers
• commercial vs government
• large IDNs or PBM-linked systems
• markets with more restrictive HTA processes
• countries with special orphan pathways

This helps tailor:

• access evidence
• contracting strategy
• pricing corridors
• local value dossiers

5. Inform pricing and contracting strategy

Consultancies can support:

• price corridor benchmarking
• analog selection
• orphan drug precedent analysis
• launch sequencing by country or segment
• access scenarios under different rebates, outcomes-based agreements, or managed entry arrangements

6. Improve internal readiness

They can also help build the internal tools your team needs:

• payer objection handling guides
• field medical and account team training
• access narrative playbooks
• country launch checklists
• evidence communication materials

How to use them effectively

Be specific about the question

Don’t ask for “payer strategy support” in general. Instead ask for targeted outputs such as:

• “What evidence is most likely to move US commercial and Medicaid payers?”
• “How should we segment EU5 access strategy for an ultra-rare therapy?”
• “What are the likely payer objections and how should we respond?”
• “Which analogs should we use for pricing justification?”

Define the deliverables

Make sure the consultancy produces tangible outputs:

• payer insight report
• value message map
• evidence gap analysis
• access risk assessment
• launch sequence recommendations
• local adaptation toolkit

Keep your team in control

Your internal team should own:

• the strategic choices
• payer priorities
• final positioning
• price and access trade-offs
• governance and compliance

The consultancy should inform, not lead, these decisions.

Use them early

They are most valuable before:

• finalizing the value story
• locking the evidence plan
• selecting pricing strategy
• preparing HTA/payer submissions

Waiting until after launch usually reduces their impact.

Common pitfalls to avoid

• Over-reliance on external advice

  • You need internal ownership of the payer strategy.

• Generic recommendations

  • Rare disease access is highly specific; insist on disease-, market-, and payer-specific insight.

• Weak integration with clinical and medical teams

  • Access strategy should align with clinical data and publication plans.

• No clear ROI

  • Set measurable goals: faster dossier readiness, improved payer message quality, better access assumptions, fewer launch surprises.

• Compliance issues

  • Ensure the consultancy’s payer research and interactions follow local rules and company SOPs.

A practical way to structure the engagement

1. Define launch objectives

   • reimbursement timing
   • target coverage
   • pricing goals
   • evidence needs

2. Commission a payer insight sprint

   • interviews, secondary research, objection mapping

3. Develop payer segments and message architecture

   • by market and stakeholder type

4. Stress-test the strategy

   • advisory boards, mock payer reviews, scenario planning

5. Translate into launch tools

   • dossiers, slide decks, FAQ, account plans, training

6. Refresh post-launch

   • incorporate early payer feedback and adjust strategy

Bottom line

Use market access consultancies to clarify what payers will value, identify evidence gaps, test your assumptions, and accelerate launch readiness. For a rare disease launch, their greatest value is helping you build a payer strategy that is credible, targeted, and adaptable despite limited data and small patient populations.

If you want, I can also give you:

1. a sample scope of work for a market access consultancy, or
2. a rare disease payer strategy framework you can use internally.